Ryoncil® Profits Underpinning Substantial Growth Pipeline

About this update from Mesoblast Limited

[{"type":"image","alt":"Mesoblast Limited","displaySize":"","headline":null,"caption":"Mesoblast Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":289,"height":38,"url":"https://media.zenfs.com/en/globenewswire.com/3a26a2f63129fae6650ef7618b48c2df"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qVvwFFYM1KHQf5WBcCEDQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/3a26a2f63129fae6650ef7618b48c2df","width":289,"height":38}},"lazy":false},{"type":"text","content":"Financial Results and Operational Update for Half-Year Ended December 31, 2025","length":78,"tagName":"p"},{"type":"text","content":"NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2025 (H1 FY2026).","length":270,"tagName":"p"},{"type":"text","content":"FINANCIAL HIGHLIGHTS FOR H1 FY20261","length":35,"tagName":"p"},{"type":"text","content":"Performance driven by successful commercial launch of Ryoncil®","length":62,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue of US$51.3 million (A$78.3 million),2 up from US$3.2 million.","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Successful U.S. commercial launch of Ryoncil® (remestemcel-L-rknd) generated gross sales of US$57.0 million and revenue of US$48.7 million after gross to net adjustment.","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"Ryoncil® gross profit, excluding amortization, was US$44.2 million versus nil in the prior year period. Direct selling costs were US$7.7 million.","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"The strong operating performance in the period allowed us to invest in R&D, including to support the Phase 3 trial on the blockbuster chronic low back pain indication, for clinical programs for lifecycle extension, and for commercial manufacturing of Ryoncil® inventory as well as for launch of second-generation product.","length":325,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported net loss of US$40.2 million compared to US$47.9 million, an improvement of US$7.8 million. Excluding a US$23.0 million inventory reversal reported in the prior ye...

More updates from Mesoblast Limited